Education for tuberculosis testing | The T-SPOT.TB test

Introducing Revvity – Expanding the boundaries of human potential through science.
All products and services previously affiliated with Oxford Immunotec are now part of Revvity.

Learn More

“We are proud to provide this education section on tuberculosis and the role that accurate diagnostics can play in controlling and eventually eradicating this disease. As you will read, the statistics of tuberculosis are staggering – the human cost of this disease is profound. The stories from TB survivors bring home the impact that this disease has on individual lives. For the last 18 years all of us at Oxford Immunotec have dedicated ourselves to diagnosing this disease better so that we can help people like Paulina, Ingrid, Kelly and Kahyr. We are proud to play our small part in this big problem.”
Peter Wrighton-Smith, CEO, Oxford Immunotec

Find out more about TB

TB eradication

There are many facts about tuberculosis (TB) that would startle most people. TB is often thought of as a problem of the past, or a problem faced in other countries. In fact, TB is still a global issue

Patient stories

The stories from TB survivors bring home the impact that this disease has on individual lives. For the last 18 years Oxford Immunotec have dedicated themselves to diagnosing this disease better so that they can help people like Paulina, Ingrid, Kelly and Kahyr.

hear their stories

Webinars

Oxford Immunotec have hosted and sponsored a number of webinars. Click on the red button below to access the recordings.

Webinar recordings

References

Global tuberculosis report 2020. Geneva: World Health Organization; 2020. CC BY-NC-SA 3.0 IGO
Oxford Immunotec. T-SPOT.TB Package Insert PI-TB-IVD-UK-v3. Abingdon, UK. 2016.
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American ThoracicSociety/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. Published online December 8, 2016:ciw694. doi:10.1093/cid/ciw694
Wong SH, Gao Q, Tsoi KKF, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2016;71:64–72.
Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep. 2010; 59(RR-5:1-25.
WHO End TB Strategy. World Health Organization. Published September 8, 2015. Accessed November 12, 2020.
Wrighton-Smith P, Sneed L, Humphrey F, Tao X, Bernacki E. Screening health care workers with interferon-γ release assay versus tuberculin skin test: Impact on costs and adherence to testing (the SWITCH study). J Occupational & Environmental Med. 2012;54(7):806-815
Oxford Immunotec. T-Cell Xtend Package Insert. PI-TT.610-UK-V6. Abingdon, UK. 2017.
Tuberculosis (TB). Centers for Disease Control and Prevention. CDC Tuberculosis. Published December 31, 2018. Accessed November 12, 2020.
Diabetes Fact Sheets. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed November 12, 2020.
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(1):17-30
RA Facts: What are the latest statistics on Rheumatoid Arthritis? Rheumatoid Arthritis Support Network. https://www.rheumatoidarthritis.org/ra/facts-and-statistics/. Accessed November 12, 2020.
The Global HIV/AIDS epidemic. HIV.gov. https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics. Accessed November 12, 2020.
Chronic Kidney Disease (CKD) Symptoms and causes. National Kidney Foundation. https://www.kidney.org/atoz/content/about-chronic-kidney-disease. Accessed November 12, 2020.
TB comorbidities and risk factors. World Health Organization. https://www.who.int/tb/areas-of-work/treatment/risk-factors/en/. Accessed November 12, 2020.
Lai CC, Tan CK, et al. Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis. J Microbiol Immunol Infect. 2011 Oct;44(5):406-7. doi: 10.1016/j.jmii.2011.07.002. Epub 2011 Sep 8.
Redelman-Sidi G, Sepkowitz KA. Interferon-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 2013; 188:422-431. 2012/12/25. DOI: 10.1164/rccm.201209-1621CI.
US – Take on TB. Centers for Disease Control and Prevention. CDC Take on Tuberculosis Infographic. Accessed January 8, 2020.
Signs & Symptoms. Centers for Disease Control and Prevention. CDC Tuberculosis Signs and Symptoms. Published March 17, 2016. Accessed January 8, 2020.
Exposure to TB. Centers for Disease Control and Prevention. CDC Exposure to TB. Published March 21, 2016. Accessed January 8, 2020.
TB Risk Factors. Centers for Disease Control and Prevention. CDC TB Risk Factors. Published March 18, 2016. Accessed January 8, 2020.
Huebner R, Schein M, Bass J. The tuberculin skin test. Clin Infect Dis. 1993;968-975.
Treatment for TB Disease. Centers for Disease Control and Prevention. CDC Treatment for TB Disease. Published April 5, 2016. Accessed January 8, 2020.